Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone + sildenafil
- Development stage
- Unknown
- Lead developer
- Gencor
- Modality
- Small Molecules
- Administration
- Sublingual, Oral
01
Overview
Libifem (in the context of Emotional Brain BV) refers to a combination drug candidate consisting of sublingual testosterone and sildenafil, developed for the treatment of female sexual dysfunction (FSD), including hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). The therapy employs a dual-mechanism approach: sublingual testosterone is intended to increase the brain's sensitivity to sexual stimuli by acting on androgen receptors, while sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, enhances peripheral physiological arousal by increasing vaginal blood flow. This combination aims to synchronize the psychological and physiological aspects of sexual response. The 'Libifem' name is primarily associated with a Phase 2 clinical trial conducted in the Netherlands that evaluated the efficacy of this combination in women with FSD. The same combination was later more widely known under the brand name Lybrido.
- Brand names
- LybridoLibifem
- Other names
- testosterone + sildenafil
02
Targets
PDE6 (Phosphodiesterase 6)AR (Adrenergic receptors)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on testosterone + sildenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone + sildenafil.